News blog

Cyprotex

• BY: Andrew Hore |
• POSTED: 20/06/2013 |

Cyprotex has started 2013 strongly but the second half will still generate more revenues.

Interim revenues should be between £4.25m and £4.45m, compared with £3.72m in the first half of 2012. This has been achieved with little or no revenues from the $10m, 5 year contract with the Environmental Protection Agency (EPA) in the US. Operating costs are in line with expectations and an operating profit of between £200,000 and £300,000 is estimated.

Cyprotex provides services to pharma companies that enable them to choose the compounds most likely to be effective and assess their potential toxicity.

The 45%/55% split between first and second halves. A 2013 operating profit of £800,000 is anticipated even without a significant contribution from the EPA contract.

At 4.62p a share, up 0.62p, Cyprotex is valued at £10.4m.

Interim figures will be published on 7 August.

Download the latest AIM Journal from http://www.hubinvest.com/AIMPDFJune2013_45.pdf